journal article·2017-12-13

MMP-2-Sensitive HA End-Conjugated Poly(amidoamine) Dendrimers via Click Reaction To Enhance Drug Penetration into Solid Tumor

Min Han, Ming-Yi Huang-Fu, Wang-Wei Guo, Ning-Ning Guo, JieJian Chen, Hui-Na Liu, Zhi-Qi Xie, Meng-Ting Lin, Qi-Chun Wei, Jian-Qing Gao

Publisher page

Abstract

Currently, the limited penetration of nanoparticles remains a major challenge for antitumor nanomedicine to penetrate into the tumor tissues. Herein, we propose a size-shrinkable drug delivery system based on a polysaccharide-modified dendrimer with tumor microenvironment responsiveness for the first time to our knowledge, which was formed by conjugating the terminal glucose of hyaluronic acid (HA) to the superficial amidogen of poly(amidoamine) (PAMAM), using a matrix metalloproteinase-2 (MMP-2)-cleavable peptide (PLGLAG) via click reaction. These nanoparticles had an initial size of ∼200 nm, but once deposited in the presence of MMP-2, they experienced a dramatic and fast size change and dissociated into their dendrimer building blocks (∼10 nm in diameter) because of cleavage of PLGLAG. This rapid size-shrinking characteristic not only promoted nanoparticle extravasation and accumulation in tumors benefited from the enhanced permeability and retention effect but also achieved faster nanoparticle diffusion and penetration. We have further conducted comparative studies of MMP-2-sensitive macromolecules (HA-pep-PAMAM) and MMP-2-insensitive macromolecules (HA-PAMAM) synthesized with a similar particle size, surface charge, and chemical composition and evaluated in both monolayer cells and multicellular spheroids. The results confirmed that the enzyme-responsive size shrink is an implementable strategy to enhance drug penetration and to improve therapeutic efficacy. Meanwhile, macromolecule-based nanoparticles with size-variable characteristics not only promote drug penetration, but they can also be used as gene delivery systems, suggesting great potential as nano-delivery systems.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Dendrimers and Hyperbranched Polymers · RNA Interference and Gene Delivery · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, P. R. China

Department of Radiation Oncology, Key Laboratory of Cancer Prevention and Intervention, the Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310058, China

Funding

Ministry of Education of the People's Republic of China · Ministry of Science and Technology of the People's Republic of China · National Natural Science Foundation of China

References (53)

Show source-provided references
1. 10.3322/caac.2116610.3322/caac.21166 ↗
2. 10.1158/0008-5472.can-07-661110.1158/0008-5472.can-07-6611 ↗
3. 10.1016/j.drudis.2006.07.00510.1016/j.drudis.2006.07.005 ↗
4. Boucher Y. · Cancer Res. · 1990 · 50 · 4478
5. 10.1016/j.jconrel.2012.11.01210.1016/j.jconrel.2012.11.012 ↗
6. 10.1007/s00396-004-1243-810.1007/s00396-004-1243-8 ↗
7. 10.1002/adma.20150286510.1002/adma.201502865 ↗
8. 10.1016/j.biomaterials.2015.05.00610.1016/j.biomaterials.2015.05.006 ↗
9. 10.1039/c5nr01408e10.1039/c5nr01408e ↗
10. 10.1021/acsami.5b0075210.1021/acsami.5b00752 ↗
11. 10.1038/nmat377610.1038/nmat3776 ↗
12. 10.1002/advs.20150022310.1002/advs.201500223 ↗
13. 10.3390/molecules2209140110.3390/molecules22091401 ↗
14. 10.1016/j.drudis.2017.06.00910.1016/j.drudis.2017.06.009 ↗
15. 10.1016/s1359-6446(01)01757-310.1016/s1359-6446(01)01757-3 ↗
16. 10.2217/nnm-2016-025210.2217/nnm-2016-0252 ↗
17. 10.1016/j.addr.2015.11.01110.1016/j.addr.2015.11.011 ↗
18. 10.1016/j.carbpol.2009.04.03710.1016/j.carbpol.2009.04.037 ↗
19. 10.1021/jacs.5b0143510.1021/jacs.5b01435 ↗
20. 10.1073/pnas.130498711010.1073/pnas.1304987110 ↗
21. 10.1002/1096-9896(2000)9999:9999<::AID-PATH632>3.0.CO;2-#10.1002/1096-9896(2000)9999:9999<::AID-PATH632>3.0.CO;2-# ↗
22. 10.1016/j.jconrel.2015.06.02410.1016/j.jconrel.2015.06.024 ↗
23. 10.1016/s1040-8428(00)00086-x10.1016/s1040-8428(00)00086-x ↗
24. 10.1016/j.jconrel.2012.04.04510.1016/j.jconrel.2012.04.045 ↗
25. 10.1038/nprot.2008.22610.1038/nprot.2008.226 ↗
26. 10.1158/0008-5472.can-08-311610.1158/0008-5472.can-08-3116 ↗
27. 10.1016/j.copbio.2007.01.00310.1016/j.copbio.2007.01.003 ↗
28. 10.1002/jps.1047010.1002/jps.10470 ↗
29. 10.1016/j.biomaterials.2013.01.07710.1016/j.biomaterials.2013.01.077 ↗
30. 10.1016/j.addr.2010.04.00910.1016/j.addr.2010.04.009 ↗
31. 10.1016/j.biomaterials.2014.10.00710.1016/j.biomaterials.2014.10.007 ↗
32. 10.1039/c3nr01447a10.1039/c3nr01447a ↗
33. 10.1016/j.biomaterials.2012.04.04410.1016/j.biomaterials.2012.04.044 ↗
34. al-Shabanah O. A. · J. Exp. Clin. Cancer Res. · 1998 · 17 · 193
35. 10.1016/j.addr.2005.09.01910.1016/j.addr.2005.09.019 ↗
36. 10.1002/hep.2080010.1002/hep.20800 ↗
37. 10.4269/ajtmh.1992.47.26510.4269/ajtmh.1992.47.265 ↗
38. 10.1016/j.jconrel.2011.09.06310.1016/j.jconrel.2011.09.063 ↗
39. 10.1007/s11095-010-0360-y10.1007/s11095-010-0360-y ↗
40. 10.1016/s0168-3659(01)00309-110.1016/s0168-3659(01)00309-1 ↗
41. 10.1158/0008-5472.can-08-378610.1158/0008-5472.can-08-3786 ↗
42. 10.1038/nm87910.1038/nm879 ↗
43. 10.1073/pnas.101889210810.1073/pnas.1018892108 ↗
44. 10.1111/j.1349-7006.2011.01929.x10.1111/j.1349-7006.2011.01929.x ↗
45. 10.1126/science.110481910.1126/science.1104819 ↗
46. 10.1158/0008-5472.can-04-007410.1158/0008-5472.can-04-0074 ↗
47. 10.1038/nm0901-98710.1038/nm0901-987 ↗
48. 10.1038/mt.2010.7910.1038/mt.2010.79 ↗
49. 10.1073/pnas.15124749810.1073/pnas.151247498 ↗
50. 10.1073/pnas.043590610010.1073/pnas.0435906100 ↗
51. 10.1016/j.jconrel.2015.07.01810.1016/j.jconrel.2015.07.018 ↗
52. 10.1021/jacs.5b0960210.1021/jacs.5b09602 ↗
53. 10.1073/pnas.040819110110.1073/pnas.0408191101 ↗